Danaher Wins Race to Acquire Abcam With $5.7 Billion Deal

Abcam research vials for antibodies.

Danaher Corp. said it will acquire Abcam Plc in a deal worth $5.7 billion, beating out rivals in a race to acquire the UK-based maker of supplies for the life-sciences industry whose technologies are used by thousands of researchers.

Danaher will pay $24 a share for the Cambridge, England based company, according to a statement Monday. The transaction, which includes debt and acquired cash, is seen closing in mid-2024, and Danaher expects to fund it using cash and debt.